Home  /  Resource Library  /  Healthcare cost comparison between first-line ibrutinib and acalabrutinib in chronic lymphocytic leukemia patients in the Veterans Affairs

Healthcare cost comparison between first-line ibrutinib and acalabrutinib in chronic lymphocytic leukemia patients in the Veterans Affairs

Study examined healthcare costs between ibrutinib and acalabrutinib for treatment of CLL.